SCHRODERS CAPITAL GLOBAL INNOVATION TRUST PLC

• ⚠

  Material uncertainty over going concern

  The company is therefore preparing its financial statements on a basis other than going concern due to the Company being in a managed wind-down.

1. SCHRODERS CAPITAL GLOBAL INNOVATION TRUST PLC 2023-04-20 → present
2. SCHRODER UK PUBLIC PRIVATE TRUST PLC 2022-09-30 → 2023-04-20
3. SCHRODERS CAPITAL GLOBAL INNOVATION TRUST PLC 2022-09-27 → 2022-09-30
4. SCHRODER UK PUBLIC PRIVATE TRUST PLC 2019-12-13 → 2022-09-27
5. WOODFORD PATIENT CAPITAL TRUST PLC 2015-01-26 → 2019-12-13

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The company is therefore preparing its financial statements on a basis other than going concern due to the Company being in a managed wind-down.”

Significant events

• “On 31 January 2025, shareholders voted overwhelmingly in favour of a managed wind-down strategy to realise assets over a reasonable timeframe and return capital to shareholders.”
• “During the year, the Company made realisations of equities totalling £39.4 million, fully exiting public equity holdings (Oxford Nanopore and Immunocore), and proceeds from sale of Carmot Therapeutics and Kymab.”
• “Post year-end, on 17 March 2025, portfolio company Araris Biotech AG agreed to be acquired by Taiho Pharmaceutical Co. Ltd for an upfront payment of $400 million, with potential additional milestones.”
• “During the year, Reaction Engines was written down to zero from £10.6 million at 31 December 2023 and entered administration on 31 October 2024.”
• “OcuTerra was revalued to zero from £4.8 million at 31 December 2023.”
• “AMO Pharma was marked down to zero at year-end.”
• “Revolut's valuation was written up by 85% in 2024, after receiving its UK banking licence with restrictions and announcing a secondary share sale at a $45 billion valuation in August 2024.”
• “The initial return of capital to shareholders is anticipated to be approximately £30 million, scheduled to occur by 30 June 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

15

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -33.1%

  £2,913,000 → £1,948,000

• Net assets

  -25.2%

  £217,064,000 → £162,445,000

• Employees

  —

  Not reported

• Profit before tax

  -46%

  -£33,798,000 → -£49,333,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers